95% effective dose of remifentanil alone for gastroscopy in obese patients under combined local anesthesia

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060091

Enrollment

Unknown

Registered

2022-05-18

Start date

2022-07-01

Completion date

Unknown

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

experimental group:Remifentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-65 years with BMI greater than 30; 2. Patients undergoing intravenous anesthesia via gastroscopy; 3. Patients with ASA grade I-III.

Exclusion criteria

Exclusion criteria: 1. Patients with bradycardia, hepatic and renal insufficiency, stroke, cerebral hemorrhage, infectious diseases, and immune system diseases before anesthesia; 2. Patients with delirium, cognitive dysfunction and other mental diseases before surgery; 3. Patients with serious mental illness; 4. Vulnerable groups such as minors, pregnant women, prisoners, students, illiterates, persons with no or limited capacity.

Design outcomes

Primary

Measure	Time frame
95% effective dose;Gastroscopy time;Incidence of nausea and vomiting;Blood pressure;Heart rate;Oxygen saturation;	—

Countries

China

Contacts

Public ContactShu Shiyu

shushiyu@hotmail.com+86 18917785284

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026